atezolizumab – Talk Bio

Exelixis’ Zanzalintinib Achieves Key Survival Goal in Pivotal Colorectal Cancer Study

2 weeks ago talkbio0Tagged atezolizumab, checkpoint inhibitor, Clinical Trials, Colorectal Carcinoma, Exelixis, Overall Survival, STELLAR-303, Stivarga, zanzalintinib

Exelixis; zanzalintinib; colorectal cancer; pivotal trial; overall survival; atezolizumab; checkpoint inhibitor; Stivarga; STELLAR-303; clinical trial

Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025

2 months ago talkbio0Tagged ASCO, atezolizumab, IMforte trial, Jazz, lurbinectedin, Malignant neoplasm of lung, Overall Survival, Progression-Free Survival, Small cell carcinoma of lung, Tecentriq, Zepzelca

Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025

Jazz Pharmaceuticals Advances Combination Therapy for Extensive-Stage Small Cell Lung Cancer

9 months ago talkbio0Tagged atezolizumab, ES-SCLC, first-line, Jazz, lurbinectedin, Phase 3 IMforte trial, Small cell carcinoma of lung, Zepzelca

Jazz Pharmaceuticals, Zepzelca, lurbinectedin, atezolizumab, ES-SCLC, first-line maintenance therapy, small cell lung cancer, Phase 3 IMforte trial

FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy

10 months ago talkbio0Tagged Approved, atezolizumab, Enhanze drug delivery technology, Hyaluronidase-tqjs, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous, Tecentriq, United States Food and Drug Administration

Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology